Analysis
PublicEITR BIOLOGICS, INC. holds $36.8M across 9 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Sep 30, 2027 PoP end — agencies typically plan 12–18 months ahead.
Contract facts
NONENo full NAICS 541714 intel page yet. Browse NAICS intelligence
THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE WORK OUTLINED IN THIS CONTRACT IS TO CRITICALLY EVALUATE THE UTILITY OF THE VHH AS A PLATFORM MCM TECHNOLOGY FOR VI
Recompete timing
PublicCurrent PoP ends Sep 30, 2027 (409 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.
Watch this contract — one email →Incumbent footprint
Public recordEITR BIOLOGICS, INC. — $36.8M obligated across 9 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Track this contract
Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.
Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.
See all live recompete landscapes — who else is expiring, and where the openings are.
Open EITR BIOLOGICS, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.
Frequently asked questions
What is contract 75A50123C00060?
75A50123C00060 (THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL O…) is a Department of Health and Human Services (HHS) award with an estimated value of $31.2M, currently held by EITR BIOLOGICS, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.
Who is the incumbent on 75A50123C00060?
EITR BIOLOGICS, INC. is the incumbent with $36.8M across 9 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2027.
When does 75A50123C00060 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 30, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →